NT—proBNP和CysC在慢性心腎綜合征早期診斷和預(yù)后評(píng)價(jià)中的研究
發(fā)布時(shí)間:2018-06-24 來(lái)源: 短文摘抄 點(diǎn)擊:
[摘要] 目的 在慢性心腎綜合征(CRS)早期診斷中檢測(cè)N末端B型氨基端利鈉肽原(NT-proBNP)和胱抑素C(CysC)及對(duì)患者預(yù)后效果的評(píng)價(jià)價(jià)值。方法 隨機(jī)抽取該院2016年5月—2017年5月收治的200例性心力衰竭(CHF)患者展開研究,將其中腎小球?yàn)V過(guò)率(GFR)低于60 mL/min的100例作為A組;其余GFR超過(guò)60 mL/min的100例作為B組,對(duì)比兩組NT-proBNP、CysC、血清肌酐(Scr)檢測(cè)結(jié)果。結(jié)果 ①A組NT-proBNP水平、CysC水平、Scr水平依次是(2.39±0.68)μg/L、(1.75±0.60)mg/L、(388.65±63.23)μmol/L,顯著高于B組的(0.82±0.12)μg/L、(0.98±0.34)mg/L、(76.22±10.31)μmol/L,比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。②A組II級(jí)患者的NT-proBNP、CysC、Scr水平低于III級(jí)(P<0.05),III級(jí)低于IV級(jí)(P<0.05)。I期慢性CRS患者的NT-proBNP水平、CysC水平、Scr水平低于II期(P<0.05);II期低于III期;III期低于IV期(P<0.05)。結(jié)論 檢測(cè)慢性CRS患者的NT-proBNP、CysC可以明確其病程程度,同時(shí)又能對(duì)預(yù)后效果給予有效評(píng)估。
[關(guān)鍵詞] 慢性心腎綜合;NT-proBNP;CysC;早期診斷;預(yù)后評(píng)價(jià)
[中圖分類號(hào)] R5 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742(2018)01(c)-0009-03
[Abstract] Objective This paper tries to evaluate the value of N-terminal pro-N-terminal pro-brain natriuretic peptide (NT-proBNP) and cystatin C (CysC) in the early diagnosis of chronic heart-kidney syndrome (CRS) and to evaluate their prognostic value. Methods A total of 200 patients with congestive heart failure (CHF) admitted to this hospital from May 2016 to May 2017 were random selected in this study. 100 patients with glomerular filtration rate (GFR) less than 60 mL/min were selected as group A; The remaining 100 cases of GFR exceeded 60 mL/min as group B, and compared the results of NT-pro BNP, CysC and serum creatinine(Scr). Results ①The levels of NT-proBNP, CysC and Scr in group A were (2.39±0.68)μg/L,(1.75±0.60)mg/L and(388.65±63.23)μmol/L, significantly higher than that of group B of respectively (0.82±0.12)μg/L, (0.98±0.34)mg/L, (76.22±10.31)μmol/L, with significant difference(P<0.05). ②NT-proBNP, CysC and Scr in group A patients with grade II were lower than grade III(P<0.05), grade III was lower than grade IV(P<0.05). The level of NT-proBNP, CysC and Scr in stage I patients with chronic CRS were lower than those in stage II(P<0.05); stage II was lower than stage III; stage III was lower than stage IV(P<0.05). Conclusion The detection of NT-proBNP and CysC in patients with chronic CRS can confirm the course of the disease and at the same time can effectively evaluate the prognosis.
[Key words] Chronic heart-kidney syndrome; NT-proBNP; CysC; Early diagnosis; Prognosis evaluation
要想對(duì)慢性CRS患者提供有效的治療方法,首先就要加強(qiáng)其早期診斷,提高診斷結(jié)果的準(zhǔn)確性,明確患者的病情程度,為臨床治療提供參考。隨著慢性CRS的患病率逐年增加,在其早期診斷中聯(lián)合檢測(cè)NT-proBNP、CysC已經(jīng)不斷受到臨床醫(yī)務(wù)人員的重視,前者屬于心功能受損標(biāo)志物,后者是反映患者腎損害、GFR變化的一項(xiàng)重要指標(biāo)[1]。為了進(jìn)一步分析這兩個(gè)指標(biāo)對(duì)慢性CRS早期診斷效果,以及對(duì)其預(yù)后效果的評(píng)估價(jià)值,該次研究隨機(jī)抽取了2016年5月—2017年5月該院收治的200例對(duì)象進(jìn)行詳細(xì)的分析,并將具體的研究情況與結(jié)果報(bào)道如下。
1 資料與方法
相關(guān)熱詞搜索:預(yù)后 綜合征 診斷 評(píng)價(jià) 研究
熱點(diǎn)文章閱讀